1. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study
- Author
-
Fei Chu, Nicholas J. Skertich, Jeffrey A. Borgia, Imad Tarhoni, Stephen Szajek, and Mary Beth Madonna
- Subjects
WT, wild type ,Herpesvirus entry mediator ,CD80, cluster of differentiation 80 ,TLR-2, Toll like receptor 2 ,RD1-811 ,PD-L1, programmed death ligand 1 ,GITRL, ligand for receptor TNFRSF18/AITR/GITR ,CTLA-4, cytotoxic T-lymphocyte-associated protein 4 ,ICOS, inducible T-cell costimulatory (ICOS) ,BTLA, B- and T-lymphocyte attenuator ,Biology ,Article ,DoxR, doxorubicin resistant ,Western blot ,medicine ,PD-L2, programmed death ligand 2 ,HVEM, herpesvirus entry mediator ,TIM-3, T-cell immunoglobulin-3 ,Matrigel ,LAG-3, lymphocyte-activation gene-3 ,CD40, cluster of differentiation 40 ,Cluster of differentiation ,medicine.diagnostic_test ,CD86, cluster of differentiation 86 ,CD27, cluster of differentiation 27 ,GITR, glucocorticoid-induced TNFR-related protein ,Ligand (biochemistry) ,medicine.disease ,PD-1, programmed death 1 ,FDA, Food and Drug Administration ,In vitro ,Cell culture ,CD28, cluster of differentiation 28 ,Cancer research ,Osteosarcoma ,Surgery - Abstract
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we investigated programmed death ligand 1 and other checkpoint molecules' expression to determine the potential usefulness as targets for drug therapy. Methods: We incubated human wild-type osteosarcoma cells with incremental concentrations of doxorubicin to create a doxorubicin-resistant cell line. Matrigel in vitro invasion assays were used to compare invasiveness. Comparative programmed death ligand 1 expression was evaluated by Western blot assays. An immuno-oncology checkpoint protein panel was used to compare concentrations of 16 other checkpoint molecules. Chi-square tests and Wilcoxon rank-sum tests were used to determine significant differences. Results: A doxorubicin-resistant cell line was successfully created and was significantly more invasive than wild-type cells (0.47 vs 0.07, P < .001). On Western blot assay, doxorubicin-resistant but not wild-type cells expressed programmed death ligand 1. Doxorubicin-resistant cells had significantly higher levels of T-cell immunoglobulin-3 and cluster of differentiation 86 and higher cluster of differentiation 27, cluster of differentiation 40, lymphocyte-activation gene-3, cluster of differentiation 80, programmed death ligand 1, programmed death ligand 2, and inducible T-cell costimulatory expression than wild-type cells. Both lines expressed B- and T-lymphocyte attenuator, cluster of differentiation 28, herpesvirus entry mediator, and programmed death 1. Herpesvirus entry mediator, cluster of differentiation 40, and programmed death ligand 2 were also present in the culture media of both cell lines. Conclusion: Doxorubicin-resistant osteosarcoma seems to express higher programmed death ligand 1 than nonresistant wild-type cells. Benchmarking checkpoint molecules may provide the basis for future studies that elucidate pathways of drug resistance and tumor metastasis, biomarkers for cancer prognosis or recurrence, and future targets for directed drug therapy.
- Published
- 2021